ALS drug trial halted early: what we know

NCT ID NCT06215755

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tested a new drug called VRG50635 in 54 people with ALS to see if it was safe and tolerable. The trial was stopped early, and its main goal was to track side effects and how the drug moves through the body. It did not aim to cure ALS, but to gather safety information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Helsinki University Hospital

    Helsinki, Uusimaa, FI-00029, Finland

  • Stan Cassidy Centre for Rehabilitation (Horizon NB)

    Montreal, Quebec, H3A 2B4, Canada

  • The Neuro - Montréal Neurological Institute-Hospital

    Montreal, Quebec, H3A 2B4, Canada

  • Turku University Hospital

    Turku, Western Finland, FI-20520, Finland

  • UZ Leuven

    Leuven, Flemish Brabant, Belgium

  • University Medical Center Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Eastern Finland, Brain Research Unit

    Kuopio, Eastern Finland, FI-70210, Finland

Conditions

Explore the condition pages connected to this study.